Identification of a clinically relevant androgen-dependent gene signature in prostate cancer Academic Article uri icon


MeSH Major

  • Biomarkers, Tumor
  • Gene Expression Profiling
  • Prostatic Neoplasms
  • Receptors, Androgen
  • Serum Response Factor


  • The androgen receptor (AR) is the principal target for treatment of non-organ-confined prostate cancer (PCa). Androgen deprivation therapies (ADT) directed against the AR ligand-binding domain do not fully inhibit androgen-dependent signaling critical for PCa progression. Thus, information that could direct the development of more effective ADTs is desired. Systems and bioinformatics approaches suggest that considerable variation exists in the mechanisms by which AR regulates expression of effector genes, pointing to a role for secondary transcription factors. A combination of microarray and in silico analyses led us to identify a 158-gene signature that relies on AR along with the transcription factor SRF (serum response factor), representing less than 6% of androgen-dependent genes. This AR-SRF signature is sufficient to distinguish microdissected benign and malignant prostate samples, and it correlates with the presence of aggressive disease and poor outcome. The AR-SRF signature described here associates more strongly with biochemical failure than other AR target gene signatures of similar size. Furthermore, it is enriched in malignant versus benign prostate tissues, compared with other signatures. To our knowledge, this profile represents the first demonstration of a distinct mechanism of androgen action with clinical relevance in PCa, offering a possible rationale to develop novel and more effective forms of ADT.

publication date

  • March 2011



  • Academic Article



  • eng

PubMed Central ID

  • PMC3077061

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.CAN-10-2512

PubMed ID

  • 21324924

Additional Document Info

start page

  • 1978

end page

  • 88


  • 71


  • 5